Enhanced gene transfer efficiency in the murine striatum and an orthotopic glioblastoma tumor model, using AAV-7- and AAV-8-pseudotyped vectors.

Cell Genesys, South San Francisco, CA 94080, USA.
Human Gene Therapy (Impact Factor: 3.62). 08/2006; 17(8):807-20. DOI: 10.1089/hum.2006.17.807
Source: PubMed

ABSTRACT In this study, recombinant AAV vectors pseudotyped with viral capsids derived from AAV serotypes 7 and 8 were evaluated for gene transfer in the murine striatum relative to vectors pseudotyped with AAV serotypes 2, 5, and 6. In comparison with rAAV serotype 2, pseudotyped vectors derived from AAV-7 and AAV-8 have increased transduction efficiency in the murine CNS, with the rank order rAAV-7 > rAAV-8 > rAAV-5 > rAAV-2 = rAAV-6, with all vectors demonstrating a marked tropism for neuronal transduction. Pseudotyped rAAV vector gene transfer in the brain after preimplantation of a murine 4C8 glioblastoma tumor was also evaluated. Efficiency of gene transfer to the orthotopic tumor was increased when using AAV-6, -7, and -8 capsid proteins in comparison with serotype 2, with the order rAAV-8 = rAAV-7 > rAAV-6 > rAAV-2 > rAAV-5. The increased gene transfer efficiency of rAAV vectors pseudotyped with the rAAV-8 capsid also provided enhanced therapeutic efficacy in a mouse model of glioblastoma multiforme, using vectors encoding an inhibitor of the vascular endothelial growth factor pathway. These studies demonstrate that rAAV vectors pseudotyped with capsids derived from AAV serotypes 7 and 8 provide enhanced gene transfer in the murine CNS and may offer increased therapeutic efficacy in the treatment of neurological disease.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Since the first reports that double-stranded RNAs can efficiently silence gene expression in C. elegans, the technology of RNA interference (RNAi) has been intensively exploited as an experimental tool to study gene function. With the subsequent discovery that RNAi could also be applied to mammalian cells, the technology of RNAi expanded from being a valuable experimental tool to being an applicable method for gene-specific therapeutic regulation, and much effort has been put into further refinement of the technique. This review will focus on how RNAi has developed over the years and how the technique is exploited in a pre-clinical and clinical perspective in relation to neurodegenerative disorders.
    09/2013; 4(3):457-84. DOI:10.3390/genes4030457
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background A deficit in impulse control is a prominent, heritable symptom in several psychiatric disorders, such as addiction, attention-deficit/ hyperactivity disorder (ADHD) and schizophrenia. Here we aimed to identify genes regulating impulsivity, specifically of impulsive action, in mice. Methods Using the widely used 5-choice serial reaction time task, we measured impulsive action in 1) a panel of 41 BXD recombinant inbred strains of mice (n = 13.7 ± 0.8 per strain; n=654 total) to detect underlying genetic loci, 2) congenic mice (n = 23) to replicate the identified locus, 3) mice overexpressing the Nrg3 candidate gene in the medial prefrontal cortex (n = 21) and 4) a Nrg3 loss-of-function mutant (n=59) to functionally implicate the Nrg3 candidate gene in impulsivity. Results Genetic mapping of impulsive action in the BXD panel identified a locus on chromosome 14 (34.5 ─ 41.4 Mb), syntenic with the human 10q22-q23 schizophrenia-susceptibility locus. Congenic mice carrying the impulsivity locus (Impu1) confirmed its influence on impulsive action. Increased impulsivity was associated with increased Nrg3 gene expression in the medial prefrontal cortex (mPFC). Viral overexpression of Nrg3 in the medial prefrontal cortex (mPFC) increased impulsivity, whereas a constitutive Nrg3 loss-of-function mutation decreased it. Conclusions The causal relation between Nrg3 expression in the mPFC and level of impulsive action shown here provides a mechanism by which polymorphism in NRG3 in humans contribute to a specific cognitive deficit seen in several psychiatric diseases, such as addiction, attention-deficit/ hyperactivity disorder (ADHD) and schizophrenia.
    Biological psychiatry 10/2014; DOI:10.1016/j.biopsych.2014.02.011 · 9.47 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A current need in the neuroscience field is a simple method to monitor autophagic activity in vivo in neurons. Until very recently, most reports have been based on correlative and static determinations of the expression levels of autophagy markers in the brain, generating conflicting interpretations. Autophagy is a fundamental process mediating the degradation of diverse cellular components, including organelles and protein aggregates at basal levels, whereas alterations in the process (i.e., autophagy impairment) operate as a pathological mechanism driving neurodegeneration in most prevalent diseases. We have recently described a new simple method to deliver and express an autophagy flux reporter through the peripheral and central nervous system of mice by the intracerebroventricular delivery of adeno-associated viruses (AAV) into newborn mice. We obtained a wide expression of a monomeric tandem mCherry-GFP-LC3 construct in neurons through the nervous system and demonstrated efficient and accurate measurements of LC3 flux after pharmacological stimulation of the pathway or in disease settings of axonal damage. Here we discuss the possible applications of this new method to assess autophagy activity in neurons in vivo.
    Autophagy 03/2014; 10(4). DOI:10.4161/auto.28434 · 11.42 Impact Factor